398 related articles for article (PubMed ID: 21855354)
21. Structure-based design of novel inhibitors of the MDM2-p53 interaction.
Rew Y; Sun D; Gonzalez-Lopez De Turiso F; Bartberger MD; Beck HP; Canon J; Chen A; Chow D; Deignan J; Fox BM; Gustin D; Huang X; Jiang M; Jiao X; Jin L; Kayser F; Kopecky DJ; Li Y; Lo MC; Long AM; Michelsen K; Oliner JD; Osgood T; Ragains M; Saiki AY; Schneider S; Toteva M; Yakowec P; Yan X; Ye Q; Yu D; Zhao X; Zhou J; Medina JC; Olson SH
J Med Chem; 2012 Jun; 55(11):4936-54. PubMed ID: 22524527
[TBL] [Abstract][Full Text] [Related]
22. Simulation of MDM2 N-terminal domain conformational lability in the presence of imidazoline based inhibitors of MDM2-p53 protein-protein interaction.
Gureev M; Novikova D; Grigoreva T; Vorona S; Garabadzhiu A; Tribulovich V
J Comput Aided Mol Des; 2020 Jan; 34(1):55-70. PubMed ID: 31781989
[TBL] [Abstract][Full Text] [Related]
23. Novel inhibitors of the MDM2-p53 interaction featuring hydrogen bond acceptors as carboxylic acid isosteres.
Gonzalez AZ; Li Z; Beck HP; Canon J; Chen A; Chow D; Duquette J; Eksterowicz J; Fox BM; Fu J; Huang X; Houze J; Jin L; Li Y; Ling Y; Lo MC; Long AM; McGee LR; McIntosh J; Oliner JD; Osgood T; Rew Y; Saiki AY; Shaffer P; Wortman S; Yakowec P; Yan X; Ye Q; Yu D; Zhao X; Zhou J; Olson SH; Sun D; Medina JC
J Med Chem; 2014 Apr; 57(7):2963-88. PubMed ID: 24601644
[TBL] [Abstract][Full Text] [Related]
24. Rational design and binding mode duality of MDM2-p53 inhibitors.
Gonzalez-Lopez de Turiso F; Sun D; Rew Y; Bartberger MD; Beck HP; Canon J; Chen A; Chow D; Correll TL; Huang X; Julian LD; Kayser F; Lo MC; Long AM; McMinn D; Oliner JD; Osgood T; Powers JP; Saiki AY; Schneider S; Shaffer P; Xiao SH; Yakowec P; Yan X; Ye Q; Yu D; Zhao X; Zhou J; Medina JC; Olson SH
J Med Chem; 2013 May; 56(10):4053-70. PubMed ID: 23597064
[TBL] [Abstract][Full Text] [Related]
25. Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction.
Ding K; Lu Y; Nikolovska-Coleska Z; Wang G; Qiu S; Shangary S; Gao W; Qin D; Stuckey J; Krajewski K; Roller PP; Wang S
J Med Chem; 2006 Jun; 49(12):3432-5. PubMed ID: 16759082
[TBL] [Abstract][Full Text] [Related]
26. Molecular hybridization design and synthesis of novel spirooxindole-based MDM2 inhibitors endowed with BCL2 signaling attenuation; a step towards the next generation p53 activators.
Lotfy G; Abdel Aziz YM; Said MM; El Ashry ESH; El Tamany ESH; Abu-Serie MM; Teleb M; Dömling A; Barakat A
Bioorg Chem; 2021 Dec; 117():105427. PubMed ID: 34794098
[TBL] [Abstract][Full Text] [Related]
27. Identification of a new class of natural product MDM2 inhibitor: In vitro and in vivo anti-breast cancer activities and target validation.
Qin JJ; Wang W; Voruganti S; Wang H; Zhang WD; Zhang R
Oncotarget; 2015 Feb; 6(5):2623-40. PubMed ID: 25739118
[TBL] [Abstract][Full Text] [Related]
28. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction based on an isoindolinone scaffold.
Hardcastle IR; Ahmed SU; Atkins H; Farnie G; Golding BT; Griffin RJ; Guyenne S; Hutton C; Källblad P; Kemp SJ; Kitching MS; Newell DR; Norbedo S; Northen JS; Reid RJ; Saravanan K; Willems HM; Lunec J
J Med Chem; 2006 Oct; 49(21):6209-21. PubMed ID: 17034127
[TBL] [Abstract][Full Text] [Related]
29. Inhibitors of the p53/hdm2 protein-protein interaction-path to the clinic.
Carry JC; Garcia-Echeverria C
Bioorg Med Chem Lett; 2013 May; 23(9):2480-5. PubMed ID: 23541651
[TBL] [Abstract][Full Text] [Related]
30. Synthesis and Optimization of New 3,6-Disubstitutedindole Derivatives and Their Evaluation as Anticancer Agents Targeting the MDM2/MDMx Complex.
Rezk MS; Abdel-Halim M; Keeton A; Franklin D; Bauer M; Boeckler FM; Engel M; Hartmann RW; Zhang Y; Piazza GA; Abadi AH
Chem Pharm Bull (Tokyo); 2016; 64(1):34-41. PubMed ID: 26726742
[TBL] [Abstract][Full Text] [Related]
31. Identification of High Affinity Non-Peptidic Small Molecule Inhibitors of MDM2-p53 Interactions through Structure-Based Virtual Screening Strategies.
Bandaru S; Ponnala D; Lakkaraju C; Bhukya CK; Shaheen U; Nayarisseri A
Asian Pac J Cancer Prev; 2015; 16(9):3759-65. PubMed ID: 25987034
[TBL] [Abstract][Full Text] [Related]
32. MDM2-p53 protein-protein interaction inhibitors: a-ring substituted isoindolinones.
Watson AF; Liu J; Bennaceur K; Drummond CJ; Endicott JA; Golding BT; Griffin RJ; Haggerty K; Lu X; McDonnell JM; Newell DR; Noble ME; Revill CH; Riedinger C; Xu Q; Zhao Y; Lunec J; Hardcastle IR
Bioorg Med Chem Lett; 2011 Oct; 21(19):5916-9. PubMed ID: 21875801
[TBL] [Abstract][Full Text] [Related]
33. Identification of new inhibitors of Mdm2-p53 interaction via pharmacophore and structure-based virtual screening.
Atatreh N; Ghattas MA; Bardaweel SK; Rawashdeh SA; Sorkhy MA
Drug Des Devel Ther; 2018; 12():3741-3752. PubMed ID: 30464405
[TBL] [Abstract][Full Text] [Related]
34.
Al-Ghabkari A; Narendran A
Cancer Biother Radiopharm; 2019 May; 34(4):252-257. PubMed ID: 30724592
[No Abstract] [Full Text] [Related]
35. Discovery of potent and selective spiroindolinone MDM2 inhibitor, RO8994, for cancer therapy.
Zhang Z; Ding Q; Liu JJ; Zhang J; Jiang N; Chu XJ; Bartkovitz D; Luk KC; Janson C; Tovar C; Filipovic ZM; Higgins B; Glenn K; Packman K; Vassilev LT; Graves B
Bioorg Med Chem; 2014 Aug; 22(15):4001-9. PubMed ID: 24997575
[TBL] [Abstract][Full Text] [Related]
36. Hitting on the move: Targeting intrinsically disordered protein states of the MDM2-p53 interaction.
Neochoritis CG; Atmaj J; Twarda-Clapa A; Surmiak E; Skalniak L; Köhler LM; Muszak D; Kurpiewska K; Kalinowska-Tłuścik J; Beck B; Holak TA; Dömling A
Eur J Med Chem; 2019 Nov; 182():111588. PubMed ID: 31421630
[TBL] [Abstract][Full Text] [Related]
37. Novel 1,4-benzodiazepine-2,5-diones as Hdm2 antagonists with improved cellular activity.
Leonard K; Marugan JJ; Raboisson P; Calvo R; Gushue JM; Koblish HK; Lattanze J; Zhao S; Cummings MD; Player MR; Maroney AC; Lu T
Bioorg Med Chem Lett; 2006 Jul; 16(13):3463-8. PubMed ID: 16647257
[TBL] [Abstract][Full Text] [Related]
38. Synthesis and evaluation of novel orally active p53-MDM2 interaction inhibitors.
Miyazaki M; Naito H; Sugimoto Y; Yoshida K; Kawato H; Okayama T; Shimizu H; Miyazaki M; Kitagawa M; Seki T; Fukutake S; Shiose Y; Aonuma M; Soga T
Bioorg Med Chem; 2013 Jul; 21(14):4319-31. PubMed ID: 23685175
[TBL] [Abstract][Full Text] [Related]
39. Tetra-substituted imidazoles as a new class of inhibitors of the p53-MDM2 interaction.
Vaupel A; Bold G; De Pover A; Stachyra-Valat T; Lisztwan JH; Kallen J; Masuya K; Furet P
Bioorg Med Chem Lett; 2014 May; 24(9):2110-4. PubMed ID: 24704029
[TBL] [Abstract][Full Text] [Related]
40. Enhanced pharmacokinetic properties of 1,4-benzodiazepine-2,5-dione antagonists of the HDM2-p53 protein-protein interaction through structure-based drug design.
Parks DJ; LaFrance LV; Calvo RR; Milkiewicz KL; Marugán JJ; Raboisson P; Schubert C; Koblish HK; Zhao S; Franks CF; Lattanze J; Carver TE; Cummings MD; Maguire D; Grasberger BL; Maroney AC; Lu T
Bioorg Med Chem Lett; 2006 Jun; 16(12):3310-4. PubMed ID: 16600594
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
